CFDE Data Portal | Search CCNO-DT

	Label	Description
	CCNO-DT Gene (Entity type)	ENSG00000251307 - CCNO divergent transcript
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE76425 0 V 12 LENALIDOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE199538 GSE199539 enzalutamide 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE174498,GSE174500 2 V 8 ASPARAGINASE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE236228 penfluridol 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 2 V 10 PALBOCICLIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE185200 GSE185202 L-13 Ali-BL 0 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

CCNO-DT

ENSG00000251307 - CCNO divergent transcript

GSE195568 palbociclib 2 v 10 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE76425 0 V 12 LENALIDOMIDE HUMAN UP

A Gene Set from LINCS

GSE199538 GSE199539 enzalutamide 2 v 1 human dn

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE174498,GSE174500 2 V 8 ASPARAGINASE HUMAN UP

A Gene Set from LINCS

GSE236228 penfluridol 0 v 1 human up

A Gene Set from LINCS

GSE195568 2 V 10 PALBOCICLIB HUMAN UP

A Gene Set from LINCS

GSE185200 GSE185202 L-13 Ali-BL 0 v 9 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.